Brokers Issue Forecasts for Alkermes FY2027 Earnings

Alkermes plc (NASDAQ:ALKS) – Stock analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Alkermes in a research note issued to investors on Wednesday, March 5th. Zacks Research analyst R. Department anticipates that the company will earn $1.15 per share for the year. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group raised their price objective on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Mizuho boosted their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Alkermes in a research report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price target for the company. Finally, UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $21.00 to $38.00 in a research report on Tuesday. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Alkermes Price Performance

NASDAQ ALKS opened at $34.65 on Thursday. The firm’s fifty day moving average price is $31.76 and its 200 day moving average price is $29.58. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 15.97, a price-to-earnings-growth ratio of 2.20 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the sale, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Cato T. Laurencin sold 2,691 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the transaction, the director now owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. This represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 309,179 shares of company stock worth $10,412,450 over the last 90 days. Company insiders own 4.89% of the company’s stock.

Hedge Funds Weigh In On Alkermes

Several hedge funds have recently added to or reduced their stakes in the business. Centiva Capital LP purchased a new position in shares of Alkermes during the 3rd quarter worth approximately $367,000. Natixis Advisors LLC increased its position in Alkermes by 190.3% during the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock worth $1,021,000 after buying an additional 23,921 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Alkermes by 254.5% in the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock worth $944,000 after acquiring an additional 23,541 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Alkermes by 74.7% during the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock valued at $4,184,000 after acquiring an additional 63,939 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Alkermes by 108.8% during the third quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after acquiring an additional 220,893 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.